PMC15 A RETROSPECTIVE ANALYSIS OF PATIENT-REPORTED OUTCOMES AND OTHER EFFICACY ENDPOINTS IN TOP BRAND NAME PRODUCT LABELS IN UNITED STATES  by Varghese, L & Lal, L
A188 Abstracts
likely as persons with Bachelor’s degree and without insurance
to rate their health as fair/poor, respectively. An additional score
of mental health status (1 [excellent] ∼ 5 [poor]) was associated
with 2.67 times more likely to have fair/poor perceived health.
The model did not suffer from signiﬁcant multicollinearity since
the maximum conditional index was less than 10. CONCLU-
SION: Health perceptions are strongly associated with standard
demographic variables like income, ethnicity and age. Future
work should address the causal factors behind these associations.
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OBJECTIVES: Patient-reported-outcomes (PROs) are endpoints
derived from the patient, collected by various means: verbally 
in a clinic, in a diary, event logs, symptom reports, or formal
instruments, to measure health status, compliance, and satisfac-
tion with treatment choices. This study determines the level of
PROs reported for the brand name drugs in the Top 200 Prod-
ucts in the US Total Market by Dispensed Total Scripts
(http://www.pharmacytimes.com), in comparison to other types
of effectiveness endpoints, such as clinician-reported-outcomes
(CROs) and laboratory values. METHODS: Brand name drugs
with web based package inserts from a list of the top 200 drugs
for 2005 were selected for inclusion in this study. Data collected
included: brand and generic names, manufacturer, therapeutic
class, and types and numbers of PROs, CROs, and laboratory
endpoints present in the package insert. RESULTS: Eighty-six
brand name drugs were included in the ﬁnal analysis, with the
highest percentages for antihypertensives and dyslipidemic
agents. Patient-reported-outcomes (PROs) were reported in 10
(11.63%) of the package inserts reviewed. Clinician-reported-
outcomes (CROs) were reported in 73 (84.88%) of the package
inserts reviewed and laboratory outcomes were reported in 23
(26.74%) of the package inserts. Twenty-three separate formal
PRO scales were utilized, with the most common ones present
in the package inserts of medications for depression, asthma, gas-
trointestinal and erectile dysfunctions. CONCLUSION: There
appears to be signiﬁcant amount of PROs and PRO instruments
that are utilized in the labeling information of the top brand
name products being sold in United States. Pharmacists and
other health care providers need to become familiar with the
formal scales and evaluation parameters of these PROs to be
effective decision makers.
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OBJECTIVES: To identify and describe differences in demo-
graphics, quality of life, resource utilization, and health care atti-
tudes between clinical trials participants and the general
population. METHODS: Data for this analysis were obtained
from the 2005 National Health and Wellness Survey (NHWS),
an annual nationally representative Internet-based study of the
health status, health care attitudes, and behaviors of adults (age
18+). The current analysis was limited to respondents from
France, Germany and the UK reporting a diagnosis of hyperten-
sion, high cholesterol, or diabetes (n = 8384). Respondents
reported ever participating in a clinical drug trial, demographic,
attitudes, resource use, and quality of life (SF-8 summary scores).
RESULTS: Across all countries, 6% (n = 472) reported ever par-
ticipating in a clinical drug trial (France, 4%; Germany, 6%; UK,
7%). In all countries, clinical trial participants were older
(France, 59.19 vs. 52.26, p < 0.01; Germany, 56.30 vs. 52.64, 
p < 0.01; UK, 59.93 vs. 56.01, p < 0.01), and had more frequent
physician visits (France, 9.17 vs. 1.01, p = 0.01; Germany, 10.27
vs. 7.47, p < 0.001; UK, 6.51 vs. 5.60, p = 0.03). Clinical trials
participants in France and Germany reported lower physical
quality of life (France, 42.98 vs. 45.91, p < 0.01; Germany, 41.97
vs. 44.11, p = 0.01) than the general population. Only trial par-
ticipants in Germany had lower mental quality of life (47.38 vs.
49.74, p < 0.01) and signiﬁcantly more emergency room visits
and hospitalizations. Trial participants in France were less likely
to have insurance than the general population (86.41% vs.
94.44%, p < 0.01). Clinical trial participants in the UK were
more likely than the general UK population to report a prefer-
ence for prescription vs. OTC medications (50.50 vs. 42.02, p =
0.02). CONCLUSION: Clinical trial participants are intrinsi-
cally different from the general population. This should be con-
sidered in the design and implementation of clinical trials and
the generalization of results to the population.
PMC17
PRINCIPAL COMPONENT ANALYSIS OF A PATIENT
SATISFACTION OF CARE SURVEY AND THE 
RELATIONSHIP BETWEEN PRINCIPAL COMPONENTS 
AND OVERALL SATISFACTION
Livengood K
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: The purpose of this study was to perform a prin-
cipal component analysis of a patient satisfaction of care survey
to determine the components or categories of questions inde-
pendent of those created by the designers of the survey. Further,
the study was ultimately intended to determine the correlation
between the principal components and overall satisfaction.
METHODS: Principal component analysis of a patient satisfac-
tion of care survey and the relationship between principal com-
ponents and overall satisfaction were performed on a patient
satisfaction survey conducted in a large health care plan in the
western United States. Fifty-seven providers were surveyed
across 25–40 patients per provider. Survey categories included
questions on the patient’s appointment; the patient’s perception
of the provider’s ofﬁce, staff, and facility; and overall satisfac-
tion with their provider. Principal component analysis was con-
ducted via factor analysis, using varimax rotation to produce
orthogonalities between components. The relationship between
principal components and overall satisfaction was evaluated
using ordinary least squares regression. RESULTS: The principal
component analysis produced four components. The ﬁrst com-
ponent contained questions related to the patient’s appointment.
The second component contained questions related to the
provider’s ofﬁce, the third component contained questions
related to the provider’s staff, and the fourth component con-
tained questions related to the provider’s facility. Overall satis-
faction had a signiﬁcant relationship with the ﬁrst and second
principal components (p < 0.001 and p < 0.05, respectively). The
third and fourth components were not signiﬁcant. CONCLU-
SION: Patients are concerned with the following elements of care
from their providers in decreasing order of importance: 1. ele-
ments related to the patient’s appointment with their provider,
2. elements related to the patient’s perception of their provider’s
ofﬁce, 3. elements related to the patient’s perception of their
provider’s staff, and 4. elements related to the patient’s percep-
tion of their provider’s facility.
